ES2596435T3 - Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia - Google Patents
Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia Download PDFInfo
- Publication number
- ES2596435T3 ES2596435T3 ES13181216.6T ES13181216T ES2596435T3 ES 2596435 T3 ES2596435 T3 ES 2596435T3 ES 13181216 T ES13181216 T ES 13181216T ES 2596435 T3 ES2596435 T3 ES 2596435T3
- Authority
- ES
- Spain
- Prior art keywords
- day
- desmopressin
- subjects
- nocturnal
- placebo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 title abstract description 35
- 229960004281 desmopressin Drugs 0.000 title abstract description 35
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 title abstract description 35
- 206010029446 nocturia Diseases 0.000 title abstract description 15
- 230000000422 nocturnal effect Effects 0.000 abstract description 29
- 238000011282 treatment Methods 0.000 abstract description 26
- 239000012458 free base Substances 0.000 abstract 1
- 239000000902 placebo Substances 0.000 description 36
- 229940068196 placebo Drugs 0.000 description 36
- 230000008859 change Effects 0.000 description 27
- 210000002700 urine Anatomy 0.000 description 23
- 230000009467 reduction Effects 0.000 description 17
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 16
- 229910052708 sodium Inorganic materials 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 15
- 230000007423 decrease Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000004622 sleep time Effects 0.000 description 9
- 206010021036 Hyponatraemia Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000004617 sleep duration Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000003860 sleep quality Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010021639 Incontinence Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5512008P | 2008-05-21 | 2008-05-21 | |
| US55120P | 2008-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2596435T3 true ES2596435T3 (es) | 2017-01-09 |
Family
ID=41100519
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13181216.6T Active ES2596435T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia |
| ES16165875.2T Active ES2677548T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia |
| ES09751584.5T Active ES2462465T5 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial del sueño no alterado por nocturia |
| ES17171152T Active ES2710454T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia |
| ES17171155T Active ES2756706T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16165875.2T Active ES2677548T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia |
| ES09751584.5T Active ES2462465T5 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial del sueño no alterado por nocturia |
| ES17171152T Active ES2710454T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia |
| ES17171155T Active ES2756706T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9974826B2 (enExample) |
| EP (5) | EP3225249B1 (enExample) |
| JP (5) | JP5767103B2 (enExample) |
| CA (1) | CA2724653A1 (enExample) |
| DK (5) | DK3225250T3 (enExample) |
| ES (5) | ES2596435T3 (enExample) |
| HR (4) | HRP20161066T1 (enExample) |
| HU (5) | HUE030409T2 (enExample) |
| LT (5) | LT3225249T (enExample) |
| LU (1) | LUC00015I2 (enExample) |
| NO (3) | NO3085381T3 (enExample) |
| PL (5) | PL2296686T5 (enExample) |
| PT (5) | PT2712622T (enExample) |
| SI (4) | SI3225250T1 (enExample) |
| TR (2) | TR201819189T4 (enExample) |
| WO (1) | WO2009143356A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| US20100286045A1 (en) * | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| DK3225250T3 (da) * | 2008-05-21 | 2019-11-04 | Ferring Bv | Orodispersibel desmopressin til forlængelse af den indledende søvnperiode, som ikke forstyrres af nykturi |
| WO2015063602A1 (en) * | 2013-10-29 | 2015-05-07 | Ferring B.V. | Desmopressin and blood glucose |
| JP7517993B2 (ja) * | 2018-10-16 | 2024-07-17 | 日本ケミファ株式会社 | 睡眠の質の改善剤 |
| CA3116290A1 (en) * | 2018-10-17 | 2020-04-23 | Nippon Chemiphar Co., Ltd. | Therapeutic or prophylactic agent for nocturnal polyuria |
| KR20230005819A (ko) * | 2020-04-14 | 2023-01-10 | 닛뽕 케미파 가부시키가이샤 | 수면의 질의 개선제 |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022103638A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH495957A (de) | 1966-09-15 | 1970-09-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4316893A (en) * | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| US4285858A (en) * | 1979-10-30 | 1981-08-25 | Mt. Sinai School Of Medicine Of The City University Of N.Y. | Vasopressin analogs |
| US4263283A (en) * | 1980-05-16 | 1981-04-21 | Ferring Pharmaceuticals, Inc. | Method for prophylaxis and/or treatment of sickle cell disease |
| GB2111423B (en) | 1981-12-02 | 1985-06-26 | Wyeth John & Brother Ltd | Making quick-dissolving pills |
| EP0084705B1 (en) | 1981-12-11 | 1987-01-14 | JOHN WYETH & BROTHER LIMITED | Process for preparing solid shaped articles |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| SE8306367L (sv) | 1983-11-18 | 1985-05-19 | Ferring Ab | Antidiuretiskt verkande farmaceutiskt preparat |
| US4863737A (en) | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
| US4588580B2 (en) * | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| IE60941B1 (en) * | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
| US4878892A (en) | 1987-02-10 | 1989-11-07 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of polypeptides |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| DK365389D0 (da) | 1989-07-24 | 1989-07-24 | Fertin Lab As | Antifungalt tyggegummipraeparat |
| US5091186A (en) * | 1989-08-15 | 1992-02-25 | Cygnus Therapeutic Systems | Biphasic transdermal drug delivery device |
| TW279133B (enExample) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| US5527288A (en) * | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| SE9101022D0 (sv) * | 1991-01-09 | 1991-04-08 | Paal Svedman | Medicinsk suganordning |
| US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| CA2070061C (en) | 1991-06-07 | 2004-02-10 | Shigeyuki Takama | Physiologically active polypeptide-containing pharmaceutical composition |
| JPH06510046A (ja) | 1991-08-26 | 1994-11-10 | アボツト・ラボラトリーズ | 治療薬の舌下または頬投与のための組成物及び方法 |
| FI943042L (fi) | 1991-12-24 | 1994-06-23 | Yamanouchi Pharma Co Ltd | Suuontelossa hajoava valmiste ja sen valmistus |
| US5298256A (en) * | 1992-04-28 | 1994-03-29 | Corint, Ltd. | Desmopressin buccal patch composition |
| US5534496A (en) * | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5343672A (en) | 1992-12-01 | 1994-09-06 | Scherer Ltd R P | Method for manufacturing freeze dried dosages in a multilaminate blister pack |
| CA2090738C (en) | 1993-02-24 | 1996-05-21 | Hema-Quebec | Use of paf |
| SE9300937L (sv) * | 1993-03-19 | 1994-09-20 | Anne Fjellestad Paulsen | Komposition för oral administrering av peptider |
| US5434121A (en) * | 1993-03-25 | 1995-07-18 | Mitsui Toatsu Chemicals, Incorporated | Variety of Drechslera monoceras, weed control compositions containing the same as an effective ingredient and weed control methods using the same |
| SE501677C2 (sv) | 1993-06-18 | 1995-04-10 | Ferring Bv | Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel |
| PT710243E (pt) * | 1993-06-29 | 2000-11-30 | Ferring Bv | Sintese melhorada de peptidos ciclicos. |
| US5985835A (en) | 1993-12-23 | 1999-11-16 | Ferring B.V. | Desmopressin for nocturia, incontinence and enuresis |
| US5500413A (en) * | 1993-06-29 | 1996-03-19 | Ferring Ab | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
| CA2166312C (en) | 1993-06-29 | 2002-04-23 | Alan Harris | Compositions for nasal administration of desmopressin |
| US5674850A (en) * | 1993-12-23 | 1997-10-07 | Ferring Ab | High purity desmopressin produced in large single batches |
| US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| JPH09510182A (ja) * | 1993-11-17 | 1997-10-14 | エルディーエス・テクノロジーズ・インコーポレーテッド | カプセル封入されたドラッグデリバリー用透明液 |
| SE9400918L (sv) * | 1994-03-18 | 1995-09-19 | Anne Fjellstad Paulsen | Stabiliserad komposition för oral administrering av peptider |
| JP2551742B2 (ja) * | 1994-05-23 | 1996-11-06 | 三星電機株式会社 | 医薬品投与用皮膚傷形成装置 |
| DE4424800A1 (de) * | 1994-07-14 | 1996-01-18 | Philips Patentverwaltung | Schaltungsanordnung zum Liefern von Speisespannungen |
| SE518619C2 (sv) * | 1994-12-09 | 2002-10-29 | Gs Dev Ab | Komposition för reglerad frisättning innehållande monokaproin |
| GB9502879D0 (en) * | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| IL113459A (en) * | 1995-04-23 | 2000-07-16 | Electromagnetic Bracing System | Electrophoretic cuff apparatus |
| US5843016A (en) | 1996-03-18 | 1998-12-01 | Physion S.R.L. | Electromotive drug administration for treatment of acute urinary outflow obstruction |
| TW411277B (en) | 1996-05-13 | 2000-11-11 | Hisamitsu Pharmaceutical Co | Percutaneous tape preparation containing fentanyl |
| GB9612629D0 (en) | 1996-06-17 | 1996-08-21 | Oxford Biosciences Ltd | Method for providing dense particle compositions for use in transdermal particle delivery |
| ATE234129T1 (de) * | 1996-06-18 | 2003-03-15 | Alza Corp | Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten |
| US5763398A (en) * | 1996-06-20 | 1998-06-09 | Ferring B.V. | Nasal administration of desmopressin |
| US5922680A (en) * | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
| SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| FR2758195B1 (fr) | 1997-01-09 | 1999-02-26 | Sgs Thomson Microelectronics | Coprocesseur d'arithmetique modulaire comprenant deux circuits de multiplication operant en parallele |
| US5821230A (en) | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US6194407B1 (en) * | 1997-07-30 | 2001-02-27 | American Home Products Corporation | Tricyclic pyrido vasopressin agonists |
| US6511974B1 (en) * | 1997-07-30 | 2003-01-28 | Wyeth | Tricyclic vasopressin agonists |
| US5932745A (en) * | 1997-07-30 | 1999-08-03 | American Home Products Corporation | Process for converting propargylic amine-N-oxides to enaminones |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US20040018241A1 (en) * | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| US6322532B1 (en) | 1998-06-24 | 2001-11-27 | 3M Innovative Properties Company | Sonophoresis method and apparatus |
| US7138393B2 (en) * | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
| US6090803A (en) * | 1998-07-24 | 2000-07-18 | American Home Products Corporation | Tricyclic vasopressin agonists |
| US6148232A (en) | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| GB9827292D0 (en) | 1998-12-12 | 1999-02-03 | Univ Strathclyde | Freeze drying |
| US6406455B1 (en) | 1998-12-18 | 2002-06-18 | Biovalve Technologies, Inc. | Injection devices |
| US20060025387A1 (en) * | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
| US6344451B1 (en) * | 1999-02-04 | 2002-02-05 | American Home Products | Pyrrolobenzodiazepine carboxyamide vasopressin agonists |
| US6620807B1 (en) | 1999-02-04 | 2003-09-16 | Wyeth | Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists |
| US6235900B1 (en) * | 1999-02-04 | 2001-05-22 | American Home Products Corporation | Tricyclic pyridine N-oxides vasopressin agonists |
| US6297234B1 (en) * | 1999-02-04 | 2001-10-02 | American Home Products Corporation | Arylthiophene vasopressin agonists |
| ATE283708T1 (de) | 1999-02-15 | 2004-12-15 | Sumitomo Pharma | Im mundraum schnellzerfallende tabletten |
| CA2362814A1 (en) * | 1999-02-18 | 2000-08-24 | Biovalve Technologies, Inc. | Electroactive pore |
| AR014640A1 (es) * | 1999-02-23 | 2001-03-28 | Univ Nac Quilmes | UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE. |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7060708B2 (en) * | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| GB2355454A (en) | 1999-10-20 | 2001-04-25 | Ferring Bv | Antidiuretic agents |
| US6558695B2 (en) * | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| GB0000079D0 (en) * | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| DE60144229D1 (de) | 2000-01-07 | 2011-04-28 | Valeritas Inc | Injektionsvorrichtung |
| US20070032410A1 (en) * | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| AT409081B (de) * | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| GB0015601D0 (en) * | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
| US6348486B1 (en) * | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
| EP2085109A3 (en) | 2000-10-26 | 2009-09-02 | Alza Corporation | Transdermal drug delivery devices having coated microprotrusions |
| US7150409B2 (en) | 2000-11-30 | 2006-12-19 | Biovalve Technologies, Inc. | Injection systems |
| ES2574917T3 (es) | 2000-11-30 | 2016-06-23 | Valeritas, Inc. | Sistemas y procedimientos de suministro y medición de fluido |
| WO2002064193A2 (en) | 2000-12-14 | 2002-08-22 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
| US7027478B2 (en) * | 2000-12-21 | 2006-04-11 | Biovalve Technologies, Inc. | Microneedle array systems |
| CN100508974C (zh) | 2001-03-16 | 2009-07-08 | 阿尔扎公司 | 施用芬太尼的经皮贴剂 |
| ES2282423T3 (es) * | 2001-04-12 | 2007-10-16 | Wyeth | Azepinas y diazepinas bi- y triciclicas n-bifenilcarbonil- y n-fenilpiridilcarbonil sustituidas como agonistas de la vasopresina. |
| US7022699B2 (en) * | 2001-04-12 | 2006-04-04 | Wyeth | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
| CN1294134C (zh) * | 2001-04-12 | 2007-01-10 | 惠氏公司 | 环己基苯基血管升压素激动剂 |
| US7615234B2 (en) * | 2001-09-11 | 2009-11-10 | Glide Pharmaceutical Technologies Limited | Drug delivery technology |
| GB2391480B (en) * | 2002-08-05 | 2007-02-28 | Caretek Medical Ltd | Drug delivery system |
| HUP0401694A3 (en) | 2001-09-13 | 2008-03-28 | Kissei Pharmaceutical | Crystal forms of a hydrochloride salt of a hydroxynorephedrine derivative, pharmaceutical compositions comprising thereof and use |
| US6723077B2 (en) * | 2001-09-28 | 2004-04-20 | Hewlett-Packard Development Company, L.P. | Cutaneous administration system |
| US6893655B2 (en) * | 2001-10-09 | 2005-05-17 | 3M Innovative Properties Co. | Transdermal delivery devices |
| MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| ATE438626T1 (de) * | 2001-11-16 | 2009-08-15 | Astellas Pharma Inc | 4,4-difluor-1,2,3,4-tetrahydro-5h-1- benzazepinderivate und deren salze |
| WO2003094886A2 (en) | 2002-05-07 | 2003-11-20 | Ferring Bv | Desmopressin in an orodispersible dosage form |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| WO2004030743A2 (en) * | 2002-09-30 | 2004-04-15 | Alza Corporation | Drug delivery device having coated microprojections incorporating vasoconstrictors |
| EP1555266B1 (en) * | 2002-10-09 | 2014-05-21 | Toray Industries, Inc. | Remedies or preventives for urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group |
| US7383084B2 (en) * | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| EP1428526A1 (en) | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
| DE10259934B3 (de) * | 2002-12-20 | 2004-10-14 | H.C. Starck Gmbh | Verfahren zur Herstellung von Formteilen aus Niob oder Tantal durch elektrochemisches Ätzen und so erhältliche Formteile |
| AR042815A1 (es) * | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| NZ542815A (en) * | 2003-04-28 | 2009-01-31 | Astellas Pharma Inc | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof |
| US20060193825A1 (en) * | 2003-04-29 | 2006-08-31 | Praecis Phamaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US7094545B2 (en) | 2003-04-30 | 2006-08-22 | Ferring Bv | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| PT1638468E (pt) | 2003-06-30 | 2007-10-10 | Alza Corp | Método para revestimento de microprojecções de perfuração da pele |
| ATE301990T1 (de) * | 2003-07-25 | 2005-09-15 | Ferring Bv | Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung |
| CN1826099B (zh) | 2003-07-25 | 2010-06-09 | 凡林有限公司 | 固体剂型药物组合物及其制造方法 |
| US6930932B2 (en) * | 2003-08-27 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Data signal reception latch control using clock aligned relative to strobe signal |
| CA2543084A1 (en) | 2003-10-24 | 2005-05-12 | Alza Corporation | Apparatus and method for enhancing transdermal drug delivery |
| CA2543086A1 (en) * | 2003-10-24 | 2005-05-12 | Alza Corporation | Pretreatment method and system for enhancing transdermal drug delivery |
| BRPI0415629A (pt) * | 2003-10-31 | 2006-12-12 | Alza Corp | aplicador auto-atuador para conjunto de microprojeções |
| WO2005046707A1 (en) * | 2003-11-10 | 2005-05-26 | Fein Seymour H | Pharmaceutical compositions including low dosages of desmopressin |
| DE60305043T2 (de) * | 2003-11-13 | 2006-11-30 | Ferring B.V. | Blisterverpackung und feste Dosierungsform enthaltend Desmopressin |
| US7018653B2 (en) * | 2003-12-29 | 2006-03-28 | Ferring B.V. | Method for preparing solid dosage form of desmopressin |
| EP1550439B1 (en) | 2003-12-29 | 2006-03-08 | Ferring B.V. | Method for preparing a solid dosage form of desmopressin |
| WO2005069758A2 (en) * | 2004-01-09 | 2005-08-04 | Alza Corporation | Frequency assisted transdermal agent delivery method and system |
| US7560100B2 (en) * | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
| US7097776B2 (en) * | 2004-10-22 | 2006-08-29 | Hewlett-Packard Development Company, L.P. | Method of fabricating microneedles |
| US20060093658A1 (en) * | 2004-10-26 | 2006-05-04 | Gayatri Sathyan | Apparatus and method for transdermal delivery of desmopressin |
| CN100339081C (zh) | 2004-11-10 | 2007-09-26 | 范敏华 | 一种氯雷他定口腔崩解片剂的制备方法 |
| US7180274B2 (en) * | 2004-12-10 | 2007-02-20 | Aimtron Technology Corp. | Switching voltage regulator operating without a discontinuous mode |
| WO2006116151A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists |
| US7856263B2 (en) | 2005-04-22 | 2010-12-21 | Travanti Pharma Inc. | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
| US20060241172A1 (en) | 2005-04-22 | 2006-10-26 | Wyeth | Benzodioxane and benzodioxolane derivatives and uses thereof |
| MX2007012936A (es) | 2005-04-22 | 2008-01-11 | Wyeth Corp | Derivados de dihidrobenzofurano y usos de los mismos. |
| TW200718692A (en) | 2005-04-22 | 2007-05-16 | Wyeth Corp | Dihydrobenzofuran derivatives and uses thereof |
| JP2008538576A (ja) | 2005-04-22 | 2008-10-30 | ワイス | クロマンおよびクロメン誘導体およびその使用 |
| GT200600162A (es) | 2005-04-24 | 2007-03-14 | Metodos para modular la funcion de la vejiga | |
| US20080213461A1 (en) | 2005-06-17 | 2008-09-04 | Georgia Tech Research Corporation | Coated Microstructures and Methods of Manufacture Thereof |
| EP1904158B1 (en) | 2005-06-24 | 2013-07-24 | 3M Innovative Properties Company | Collapsible patch with microneedle array |
| WO2007083323A2 (en) | 2006-01-23 | 2007-07-26 | Panacea Biotec Limited. | Modified release oral dosage form comprising desmopressin |
| CA2584456C (en) | 2006-03-02 | 2008-07-22 | Ferring International Center S.A. | Composition comprising desmopressin |
| WO2007127976A2 (en) | 2006-05-01 | 2007-11-08 | Georgia Tech Research Corporation | Particle based molding |
| RU2472539C2 (ru) | 2007-08-06 | 2013-01-20 | Аллерган, Инк. | Способы и устройства для доставки препарата десмопрессина |
| DK3225250T3 (da) * | 2008-05-21 | 2019-11-04 | Ferring Bv | Orodispersibel desmopressin til forlængelse af den indledende søvnperiode, som ikke forstyrres af nykturi |
-
2009
- 2009-05-21 DK DK17171155T patent/DK3225250T3/da active
- 2009-05-21 JP JP2011510705A patent/JP5767103B2/ja active Active
- 2009-05-21 NO NO16165875A patent/NO3085381T3/no unknown
- 2009-05-21 ES ES13181216.6T patent/ES2596435T3/es active Active
- 2009-05-21 PL PL09751584T patent/PL2296686T5/pl unknown
- 2009-05-21 EP EP17171152.6A patent/EP3225249B1/en active Active
- 2009-05-21 PL PL17171152T patent/PL3225249T3/pl unknown
- 2009-05-21 HU HUE13181216A patent/HUE030409T2/en unknown
- 2009-05-21 TR TR2018/19189T patent/TR201819189T4/tr unknown
- 2009-05-21 EP EP17171155.9A patent/EP3225250B1/en active Active
- 2009-05-21 LT LTEP17171152.6T patent/LT3225249T/lt unknown
- 2009-05-21 PT PT131812166T patent/PT2712622T/pt unknown
- 2009-05-21 DK DK09751584.5T patent/DK2296686T4/en active
- 2009-05-21 PT PT17171152T patent/PT3225249T/pt unknown
- 2009-05-21 EP EP09751584.5A patent/EP2296686B2/en active Active
- 2009-05-21 DK DK13181216.6T patent/DK2712622T3/en active
- 2009-05-21 EP EP16165875.2A patent/EP3085381B1/en active Active
- 2009-05-21 PL PL13181216T patent/PL2712622T3/pl unknown
- 2009-05-21 SI SI200932000T patent/SI3225250T1/sl unknown
- 2009-05-21 DK DK17171152.6T patent/DK3225249T3/en active
- 2009-05-21 SI SI200931494A patent/SI2712622T1/sl unknown
- 2009-05-21 TR TR2018/07224T patent/TR201807224T4/tr unknown
- 2009-05-21 LT LTEP13181216.6T patent/LT2712622T/lt unknown
- 2009-05-21 PL PL16165875T patent/PL3085381T3/pl unknown
- 2009-05-21 WO PCT/US2009/044860 patent/WO2009143356A1/en not_active Ceased
- 2009-05-21 SI SI200931838T patent/SI3085381T1/en unknown
- 2009-05-21 ES ES16165875.2T patent/ES2677548T3/es active Active
- 2009-05-21 EP EP13181216.6A patent/EP2712622B1/en active Active
- 2009-05-21 HU HUE17171152A patent/HUE041370T2/hu unknown
- 2009-05-21 US US12/469,801 patent/US9974826B2/en active Active
- 2009-05-21 DK DK16165875.2T patent/DK3085381T3/en active
- 2009-05-21 LT LTEP16165875.2T patent/LT3085381T/lt unknown
- 2009-05-21 PL PL17171155T patent/PL3225250T3/pl unknown
- 2009-05-21 SI SI200931912T patent/SI3225249T1/sl unknown
- 2009-05-21 ES ES09751584.5T patent/ES2462465T5/es active Active
- 2009-05-21 PT PT171711559T patent/PT3225250T/pt unknown
- 2009-05-21 PT PT97515845T patent/PT2296686E/pt unknown
- 2009-05-21 HU HUE17171155A patent/HUE046050T2/hu unknown
- 2009-05-21 NO NO09751584A patent/NO2296686T3/no unknown
- 2009-05-21 HU HUE16165875A patent/HUE039013T4/hu unknown
- 2009-05-21 ES ES17171152T patent/ES2710454T3/es active Active
- 2009-05-21 LT LT17171155T patent/LT3225250T/lt unknown
- 2009-05-21 PT PT161658752T patent/PT3085381T/pt unknown
- 2009-05-21 ES ES17171155T patent/ES2756706T3/es active Active
- 2009-05-21 CA CA2724653A patent/CA2724653A1/en not_active Abandoned
-
2015
- 2015-03-31 JP JP2015072698A patent/JP6001121B2/ja active Active
-
2016
- 2016-08-22 HR HRP20161066TT patent/HRP20161066T1/hr unknown
- 2016-08-31 JP JP2016169163A patent/JP6258424B2/ja active Active
-
2017
- 2017-01-20 LT LTPA2017001C patent/LTC2712622I2/lt unknown
- 2017-04-12 LU LU00015C patent/LUC00015I2/fr unknown
- 2017-12-06 JP JP2017234382A patent/JP6506821B2/ja active Active
-
2018
- 2018-01-26 US US15/880,697 patent/US20180250357A1/en not_active Abandoned
- 2018-05-17 HR HRP20180774TT patent/HRP20180774T1/hr unknown
-
2019
- 2019-01-18 HR HRP20190114TT patent/HRP20190114T1/hr unknown
- 2019-03-29 JP JP2019067813A patent/JP6836618B2/ja active Active
- 2019-04-26 HU HUS1900024C patent/HUS1900024I1/hu unknown
- 2019-04-30 NO NO2019021C patent/NO2019021I1/no unknown
- 2019-10-14 HR HRP20191854TT patent/HRP20191854T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2596435T3 (es) | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia | |
| US11020448B2 (en) | Methods comprising desmopressin | |
| Torres et al. | Rationale and design of a clinical trial investigating tolvaptan safety and efficacy in autosomal dominant polycystic kidney disease | |
| Ehrlich et al. | The use of chlorpropamide in diabetes insipidus in children | |
| Barkin | Nocturia: diagnosis and management for the primary care physicians | |
| US11963995B2 (en) | Methods comprising desmopressin | |
| Fedele et al. | Effects of medication on parotid salivary flow rates in an individual with dementia of the Alzheimer type | |
| Feuchtbaum et al. | Alvimopan for the reduction of postoperative ileus after long posterior spinal fusion: placebo-controlled double-blind randomized trial | |
| NI | A Randomised Control Trial of Nifedipine Versus Captopril for the Treatment of Hypertension in Children with Acute Post-Streptococcal Glomerulonephritis. | |
| Yoon et al. | Primary mono-symptomatic nocturnal enuresis: A review of management | |
| Farrington | Atomized lidocaine prior to nasogastric tube placement | |
| Ogundipe et al. | Hyponatraemia associated with the use of a proton pump inhibitor | |
| Tennant | Adrenocorticotropin (acth) as a biomarker of uncontrolled pain | |
| Prajapati et al. | Olanzapine Induced Tardive Dystonia | |
| Molokie et al. | Predictors of morphine and hydromorphone doses for patients with sickle cell disease in an urban day hospital and emergency department | |
| HK1238572B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia |